Asterias Biotherapeutics Warrants
AST.WS
AST.WS was delisted on the 26th of September, 2017.
37 hedge funds and large institutions have $72.2K invested in Asterias Biotherapeutics Warrants in 2016 Q2 according to their latest regulatory filings, with 37 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$95.3K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$46.8K |
| 3 |
Bridgeway Capital Management
Houston,
Texas
|
+$15.4K |
| 4 |
Goldman Sachs
New York
|
+$9.7K |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$9.14K |
Top Sellers
AST.WS Hedge Fund Activity: Q2 2016 in Review
37 of the 3,756 institutional investors tracked by Wall St. Rank reported a position in Asterias Biotherapeutics Warrants (AST.WS) for Q2 2016, worth a combined $72.2K.
Buyers outnumbered sellers: 37 funds opened new AST.WS positions and 0 closed out — a net gain of 37 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Fidelity Investments, opening a new position worth an estimated $95.3K.
- 37 institutional investors held Asterias Biotherapeutics Warrants (AST.WS) as of Q2 2016, up from 0 in Q1 2016.
- Funds reported $72.2K of Asterias Biotherapeutics Warrants stock for Q2 2016.
- 37 funds opened new Asterias Biotherapeutics Warrants positions in Q2 2016 and 0 closed out, a net change of +37 holders.
- The largest Asterias Biotherapeutics Warrants buyer in Q2 2016 was Fidelity Investments, an estimated $95.3K added.
Based on aggregated 13F filings for Q2 2016.